{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:40Z","timestamp":1787181940785,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["SVV 260760"],"award-info":[{"award-number":["SVV 260760"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["AZV NW26-03-00152"],"award-info":[{"award-number":["AZV NW26-03-00152"]}],"id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["MCL 7005-24"],"award-info":[{"award-number":["MCL 7005-24"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-55062-2","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:54:11Z","timestamp":1780930451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas"],"prefix":"10.1038","volume":"16","author":[{"given":"Eva","family":"Pokorna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Manakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristyna","family":"Nozickova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Kovarikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dolnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol","family":"Renesova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Tuskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Klanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Vreckova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Havranek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"55062_CR1","first-page":"1","volume":"42","author":"A Kumar","year":"2022","unstructured":"Kumar, A., Eyre, T. A., Lewis, K. L., Thompson, M. C. & Cheah, C. Y. New Directions for mantle cell lymphoma in 2022. Am Soc Clin Oncol Educ Book. 42, 1\u201315 (2022).","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"55062_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bjh.17419","volume":"195","author":"E Silkenstedt","year":"2021","unstructured":"Silkenstedt, E., Linton, K. & Dreyling, M. Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches. Br. J. Haematol. 195, 162\u2013173 (2021).","journal-title":"Br. J. Haematol."},{"key":"55062_CR3","first-page":"413","volume":"84","author":"E Cabezudo","year":"1999","unstructured":"Cabezudo, E., Carrara, P., Morilla, R. & Matutes, E. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica 84, 413\u2013418 (1999).","journal-title":"Haematologica"},{"key":"55062_CR4","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre, T. A. et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica 104, e68\u2013e71 (2019).","journal-title":"Haematologica"},{"key":"55062_CR5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","volume":"26","author":"CY Cheah","year":"2015","unstructured":"Cheah, C. Y. et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 26, 1175\u20131179 (2015).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"55062_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16416","author":"R McCulloch","year":"2020","unstructured":"McCulloch, R. et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br. J. Haematol. https:\/\/doi.org\/10.1111\/bjh.16416 (2020).","journal-title":"Br. J. Haematol."},{"key":"55062_CR7","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. J. clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 41, 2594\u20132606 (2023).","journal-title":"J. clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"55062_CR8","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","volume":"6","author":"G Iacoboni","year":"2022","unstructured":"Iacoboni, G. et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 6, 3606\u20133610 (2022).","journal-title":"Blood Adv."},{"key":"55062_CR9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood.2021013326","volume":"139","author":"TA Eyre","year":"2022","unstructured":"Eyre, T. A., Cheah, C. Y. & Wang, M. L. Therapeutic options for relapsed\/refractory mantle cell lymphoma. Blood 139, 666\u2013677 (2022).","journal-title":"Blood"},{"key":"55062_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato, A. R. et al. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N. Engl. J. Med. 389, 33\u201344 (2023).","journal-title":"N. Engl. J. Med."},{"key":"55062_CR11","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang, M. L. et al. Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J. clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 41, 3988\u20133997 (2023).","journal-title":"J. clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"55062_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.23.02470","volume":"43","author":"TJ Phillips","year":"2025","unstructured":"Phillips, T. J. et al. Glofitamab in relapsed\/refractory mantle cell lymphoma: Results from a phase I\/II study. J. Clin. Oncol. 43, 318\u2013328 (2025).","journal-title":"J. Clin. Oncol."},{"key":"55062_CR13","doi-asserted-by":"crossref","unstructured":"Wang ML, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, et al. Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. NEJM Evid. 2022;1:EVIDoa2100001.","DOI":"10.1056\/EVIDoa2100001"},{"key":"55062_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn, L. H. & Salles, G. Diffuse large B-cell lymphoma. N. Engl. J. Med. 384, 842\u2013858 (2021).","journal-title":"N. Engl. J. Med."},{"key":"55062_CR15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","volume":"16","author":"MC Palanca-Wessels","year":"2015","unstructured":"Palanca-Wessels, M. C. et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 16, 704\u2013715 (2015).","journal-title":"Lancet Oncol."},{"key":"55062_CR16","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"55062_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"55062_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"55062_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2217\/fon-2020-0675","volume":"17","author":"V Camus","year":"2021","unstructured":"Camus, V. & Tilly, H. Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed\/refractory diffuse large B-cell lymphoma. Future Oncol. (London, England) 17, 127\u2013135 (2021).","journal-title":"Future Oncol. (London, England)"},{"key":"55062_CR20","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019:Jco1900172."},{"key":"55062_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/jha2.655","volume":"4","author":"VM Perriello","year":"2023","unstructured":"Perriello, V. M. et al. Polatuzumab-bendamustine-rituximab as bridge to CD19-directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax. EJHaem 4, 559\u2013562 (2023).","journal-title":"EJHaem"},{"key":"55062_CR22","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. The New England journal of medicine. 2021."},{"key":"55062_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ajh.26809","volume":"98","author":"EA Lasater","year":"2023","unstructured":"Lasater, E. A. et al. Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R\/R non-Hodgkin lymphoma: Results from preclinical models and a phase Ib study. Am. J. Hematol. 98, 449\u2013463 (2023).","journal-title":"Am. J. Hematol."},{"key":"55062_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41420-025-02341-y","volume":"11","author":"L Daumova","year":"2025","unstructured":"Daumova, L. et al. Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitors. Cell Death Discov. 11, 65 (2025).","journal-title":"Cell Death Discov."},{"key":"55062_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681 (2006).","journal-title":"Pharmacol. Rev."},{"key":"55062_CR26","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41374-022-00784-w","volume":"102","author":"R Jak\u0161a","year":"2022","unstructured":"Jak\u0161a, R. et al. Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas. Lab Invest. 102, 957\u2013965 (2022).","journal-title":"Lab Invest."},{"key":"55062_CR27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/labinvest.2014.61","volume":"94","author":"M Klanova","year":"2014","unstructured":"Klanova, M. et al. Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research. Lab Invest. 94, 806\u2013817 (2014).","journal-title":"Lab Invest."},{"key":"55062_CR28","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res."},{"key":"55062_CR29","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"key":"55062_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"55062_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature09779","volume":"471","author":"IE Wertz","year":"2011","unstructured":"Wertz, I. E. et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471, 110\u2013114 (2011).","journal-title":"Nature"},{"key":"55062_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1226289","volume":"13","author":"SI Tantawy","year":"2023","unstructured":"Tantawy, S. I., Timofeeva, N., Sarkar, A. & Gandhi, V. Targeting MCL-1 protein to treat cancer: Opportunities and challenges. Front. Oncol. 13, 1226289 (2023).","journal-title":"Front. Oncol."},{"key":"55062_CR33","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1182\/blood-2015-09-672352","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy, B. et al. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood 127, 2203\u20132213 (2016).","journal-title":"Blood"},{"key":"55062_CR34","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/leu.2015.48","volume":"29","author":"M Pfeifer","year":"2015","unstructured":"Pfeifer, M. et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia 29, 1578\u20131586 (2015).","journal-title":"Leukemia"},{"key":"55062_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly, H. et al. Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma. N. Engl. J. Med. 386, 351\u2013363 (2022).","journal-title":"N. Engl. J. Med."},{"key":"55062_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1158\/1078-0432.CCR-25-2392","volume":"32","author":"ERS Cliff","year":"2026","unstructured":"Cliff, E. R. S. et al. Cell-of-origin subtype predicts response to polatuzumab vedotin in large B-cell lymphoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 32, 159\u2013168 (2026).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"55062_CR37","first-page":"2721","volume":"114","author":"D Dornan","year":"2009","unstructured":"Dornan, D. et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114, 2721\u20132729 (2009).","journal-title":"Blood"},{"key":"55062_CR38","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1158\/2159-8290.CD-23-0802","volume":"14","author":"SR Corcoran","year":"2024","unstructured":"Corcoran, S. R. et al. Molecular determinants of sensitivity to Polatuzumab Vedotin in diffuse large B-cell lymphoma. Cancer Discov. 14, 1653\u20131674 (2024).","journal-title":"Cancer Discov."},{"key":"55062_CR39","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/15384101.2025.2484868","volume":"23","author":"M El-Mesery","year":"2024","unstructured":"El-Mesery, M., Rudolf, F., Heimann, Y., H\u00e4cker, G. & Brunner, T. Non-canonical functions of BCL-2 family members in energy metabolism and necrotic cell death regulation. Cell Cycle 23, 931\u2013948 (2024).","journal-title":"Cell Cycle"},{"key":"55062_CR40","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/ni.3348","volume":"17","author":"J Tellier","year":"2016","unstructured":"Tellier, J. et al. Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response. Nat. Immunol. 17, 323\u2013330 (2016).","journal-title":"Nat. Immunol."},{"key":"55062_CR41","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1002\/ijc.31369","volume":"143","author":"J Ketteler","year":"2018","unstructured":"Ketteler, J. & Klein, D. Caveolin-1, cancer and therapy resistance. Int. J. Cancer 143, 2092\u20132104 (2018).","journal-title":"Int. J. Cancer"},{"key":"55062_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102043","volume":"88","author":"L Mele","year":"2020","unstructured":"Mele, L. et al. The role of autophagy in resistance to targeted therapies. Cancer Treat. Rev. 88, 102043 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"55062_CR43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn, L. H. et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. Off. J. Am. Soci. Clin. Oncol. 38, 155\u2013165 (2020).","journal-title":"J. Clin. Oncol. Off. J. Am. Soci. Clin. Oncol."},{"key":"55062_CR44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","volume":"6","author":"LH Sehn","year":"2022","unstructured":"Sehn, L. H. et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 6, 533\u2013543 (2022).","journal-title":"Blood Adv."},{"key":"55062_CR45","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood-2023-174956","volume":"142","author":"ML Wang","year":"2023","unstructured":"Wang, M. L. et al. Fixed duration Mosunetuzumab plus Polatuzumab Vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: Initial results from a Phase Ib\/II study. Blood 142, 734 (2023).","journal-title":"Blood"},{"key":"55062_CR46","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","volume":"25","author":"D Prukova","year":"2019","unstructured":"Prukova, D. et al. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed Mantle Cell Lymphoma. Clin. Cancer Res. 25, 4455\u20134465 (2019).","journal-title":"Clin. Cancer Res."},{"key":"55062_CR47","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1038\/s41388-019-1122-x","volume":"39","author":"MA Dengler","year":"2020","unstructured":"Dengler, M. A. et al. Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. Oncogene 39, 2009\u20132023 (2020).","journal-title":"Oncogene"},{"key":"55062_CR48","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/leu.2017.243","volume":"32","author":"TC Teh","year":"2018","unstructured":"Teh, T. C. et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia 32, 303\u2013312 (2018).","journal-title":"Leukemia"},{"key":"55062_CR49","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/leu.2015.99","volume":"29","author":"L Li","year":"2015","unstructured":"Li, L. et al. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia 29, 1702\u20131712 (2015).","journal-title":"Leukemia"},{"key":"55062_CR50","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3324\/haematol.2022.282031","volume":"108","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma. Haematologica 108, 1412\u20131416 (2023).","journal-title":"Haematologica"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55062-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55062-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55062-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:05:17Z","timestamp":1787180717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55062-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55062"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55062-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26090"}}